Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ENAH |
| Gene Name: | ENAH |
| Protein Full Name: | Protein enabled homolog |
| Alias: | Enabled; FLJ10773; MENA; NDPP1 |
| Mass (Da): | 66510 |
| Number AA: | 591 |
| UniProt ID: | Q8N8S7 |
| Locus ID: | 55740 |
| COSMIC ID: | ENAH |
| Gene location on chromosome: | 1q42.12 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.55 |
| Normal role description: | Links the receptor-tyrosine kinase pathways (EGF, Neuregulin) with actin cytoskeleton system. Levels increase with tumour progression in many different human cancers. At times this is mediated through constituent activation of the receptor pathways and is thus responsive to RTK inhibitor therapy (herceptin, erlotinib). |